XNK Therapeutics AB’s CEO Johan Liwing will present at Redeye’s Regenerative Medicine/Cell Therapy event on February 23 at 09.50 CET. The presentation is broadcasted live and can be followed at: https://www.redeye.se/events/825130/redeye-theme-regenerative-medicine-cell-therapy
The presentation will be available online on XNK Therapeutics’ website https://xnktherapeutics.com shortly after the event.
For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company is at the forefront of the development of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and lead investigational candidate drug was developed specifically to target cancers, including settings where allogeneic cell products are not readily applicable. The Company’s objective is for its investigational candidate drug and proprietary platform technology to constitute key components in the cancer treatments of tomorrow. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.